Recent Bills
- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
Committees
- AdministrationU.S. House
- AgricultureU.S. House
- Agriculture, Nutrition, And ForestryU.S. House
- AppropriationsU.S. House
- Armed ServicesU.S. House
- Banking, Housing, And Urban AffairsU.S. House
- BudgetU.S. House
- Commerce, Science, And TransportationU.S. House
- Education and WorkforceU.S. House
- Energy And CommerceU.S. House
- Energy And Natural ResourcesU.S. House
- Environment And Public WorksU.S. House
- EthicsU.S. House
- FinanceU.S. House
- Financial ServicesU.S. House
- Foreign AffairsU.S. House
- Foreign RelationsU.S. House
- Health, Education, Labor, And PensionsU.S. House
- Homeland SecurityU.S. House
- Homeland Security And Governmental Affa…U.S. House
- Indian AffairsU.S. House
- Indian and Insular AffairsU.S. House
- IntelligenceU.S. House
- JudiciaryU.S. House
- Natural ResourcesU.S. House
- Oversight And Government ReformU.S. House
- Permanent Select IntelligenceU.S. House
- RulesU.S. House
- Rules And AdministrationU.S. House
- Science, Space, And TechnologyU.S. House
- Select IntelligenceU.S. Senate
- Small BusinessU.S. House
- Small Business And EntrepreneurshipU.S. House
- Subcommittee on AviationU.S. House
- Subcommittee on Border Security and Enf…U.S. House
- Subcommittee on Coast Guard and Maritim…U.S. House
- Subcommittee on Commodity Markets, Digi…U.S. House
- Subcommittee on Conservation, Research,…U.S. House
- Subcommittee on Counterterrorism and In…U.S. House
- Subcommittee on Cybersecurity and Infra…U.S. House
- Subcommittee on Disability Assistance a…U.S. House
- Subcommittee on Economic Development, P…U.S. House
- Subcommittee on Economic OpportunityU.S. House
- Subcommittee on Emergency Management an…U.S. House
- Subcommittee on Energy and Mineral Reso…U.S. House
- Subcommittee on Federal LandsU.S. House
- Subcommittee on Forestry and Horticultu…U.S. House
- Subcommittee on General Farm Commoditie…U.S. House
- Subcommittee on HealthU.S. House
- Subcommittee on Highways and TransitU.S. House
- Subcommittee on Livestock, Dairy, and P…U.S. House
- Subcommittee on Nutrition and Foreign A…U.S. House
- Subcommittee on Oversight and Investiga…U.S. House
- Subcommittee on Oversight, Investigatio…U.S. House
- Subcommittee on Railroads, Pipelines, a…U.S. House
- Subcommittee on Transportation and Mari…U.S. House
- Subcommittee on Water Resources and Env…U.S. House
- Subcommittee on Water, Wildlife and Fis…U.S. House
- Transportation And InfrastructureU.S. House
- Veterans' AffairsU.S. House
- Ways And MeansU.S. House

HB 527
Utah House•Passed
Summary
HB 527, “Pharmacy Pricing Amendments”, was introduced in the House on Feb 9, 2026 by Rep. Katy Hall (R) with 1 co-sponsor. It last saw action on Mar 19, 2026: Governor Signed in Lieutenant Governor's office for filing.
Record
Text
HB 527 has 1 co-sponsor and 6 roll calls.
hb527/enrolled.txtEnrolled Copy H.B. 5271Pharmacy Pricing Amendments2026 GENERAL SESSIONSTATE OF UTAHChief Sponsor: Katy HallSenate Sponsor: Evan J. Vickers23 LONG TITLE4 General Description:5 This bill amends provisions related to pharmacy benefits.6 Highlighted Provisions:7 This bill:8 ▸ defines terms;9 ▸ amends provisions related to drug maximum allowable cost, including regarding lists,10 appeals, and claims;11 ▸ specifies penalties; and12 ▸ provides the Insurance Department rulemaking authority.13 Money Appropriated in this Bill:14 None15 Other Special Clauses:16 None17 Utah Code Sections Affected:18 AMENDS:19 31A-46-102, as last amended by Laws of Utah 2025, Chapter 52520 31A-46-303, as last amended by Laws of Utah 2020, Chapters 198, 27521 31A-46-401, as enacted by Laws of Utah 2019, Chapter 24122 ENACTS:23 31A-46-103, Utah Code Annotated 19532425 Be it enacted by the Legislature of the state of Utah:26Section 1. Section 31A-46-102 is amended to read:2731A-46-102 . Definitions.H.B. 527 Enrolled Copy28 As used in this chapter:29 (1) "340B drug" means a drug purchased through the 340B drug discount program by a30340B entity.31 (2) "340B drug discount program" means the 340B drug discount program described in 4232U.S.C. Sec. 256b.33 (3) "340B entity" means:34(a) an entity participating in the 340B drug discount program;35(b) a pharmacy of an entity participating in the 340B drug discount program; or36(c) a pharmacy contracting with an entity participating in the 340B drug discount37program to dispense drugs purchased through the 340B drug discount program.38 (4) "Administrative fee" means any payment, other than a rebate, that a pharmaceutical39manufacturer makes directly or indirectly to a pharmacy benefit manager.40 (5) "Allowable claim amount" means the amount paid by an insurer under the customer's41health benefit plan.42 (6) "Contracting insurer" means an insurer with whom a pharmacy benefit manager43contracts to provide a pharmacy benefit management service.44 (7) "Cost share" means the amount paid by an insured customer under the customer's health45benefit plan.46 (8) "Direct or indirect remuneration" means any adjustment in the total compensation:47(a) received by a pharmacy from a pharmacy benefit manager for the sale of a drug,48device, or other product or service; and49(b) that is determined after the sale of the product or service.50 (9) "Dispense" means the same as that term is defined in Section 58-17b-102.51 (10) "Drug" means the same as that term is defined in Section 58-17b-102.52 (11) "Insurer" means the same as that term is defined in Section 31A-22-636.53 (12) "Maximum allowable cost" means:54(a) a maximum reimbursement amount for a group of pharmaceutically and55therapeutically equivalent drugs; or56(b) any similar reimbursement amount that is used by a pharmacy benefit manager to57reimburse pharmacies for multiple source drugs.58 (13) "Medicaid program" means the same as that term is defined in Section 26B-3-101.59 (14) "Obsolete" means a product that may be listed in national drug pricing compendia but60is no longer available to be dispensed based on the expiration date of the last lot61manufactured.-2-Enrolled Copy H.B. 52762 (15) "Patient counseling" means the same as that term is defined in Section 58-17b-102.63 (16) "Pharmacy acquisition cost" means the net amount that a pharmaceutical wholesaler64 charges for a pharmaceutical product.65 [(16)] (17) "Pharmaceutical facility" means the same as that term is defined in Section66 58-17b-102.67 [(17)] (18) "Pharmaceutical manufacturer" means a pharmaceutical facility that68 manufactures prescription drugs.69 [(18)] (19) "Pharmacist" means the same as that term is defined in Section 58-17b-102.70 [(19)] (20) "Pharmacy" means the same as that term is defined in Section 58-17b-102.71 [(20)] (21) "Pharmacy benefits management service" means any of the following services72 provided to a health benefit plan, or to a participant of a health benefit plan:73 (a) negotiating the amount to be paid by a health benefit plan for a prescription drug; or74 (b) administering or managing a prescription drug benefit provided by the health benefit75plan for the benefit of a participant of the health benefit plan, including administering76or managing:77(i) an out-of-state mail service pharmacy;78(ii) a specialty pharmacy;79(iii) claims processing;80(iv) payment of a claim;81(v) retail network management;82(vi) clinical formulary development;83(vii) clinical formulary management services;84(viii) rebate contracting;85(ix) rebate administration;86(x) a participant compliance program;87(xi) a therapeutic intervention program;88(xii) a disease management program; or89(xiii) a service that is similar to, or related to, a service described in Subsection90(20)(a) or this Subsection (20)(b).91 [(21)] (22) "Pharmacy benefit manager" means a person licensed under this chapter to92 provide a pharmacy benefits management service.93 [(22)] (23) "Pharmacy service" means a product, good, or service provided to an individual94 by a pharmacy or pharmacist.95 [(23)] (24) "Pharmacy services administration organization" means an entity that contracts-3-H.B. 527 Enrolled Copy96with a pharmacy to assist with third-party payer interactions and administrative services97related to third-party payer interactions, including:98(a) contracting with a pharmacy benefit manager on behalf of the pharmacy; and99(b) managing a pharmacy's claims payments from third-party payers.100 [(24)] (25) "Pharmacy service entity" means:101(a) a pharmacy services administration organization; or102(b) a pharmacy benefit manager.103 [(25)] (26) "Prescription device" means the same as that term is defined in Section10458-17b-102.105 [(26)] (27) "Prescription drug" means the same as that term is defined in Section 58-17b-102.106 [(27)] (28)(a) "Rebate" means a refund, discount, or other price concession that is paid by107a pharmaceutical manufacturer to a pharmacy benefit manager based on a108prescription drug's utilization or effectiveness.109(b) "Rebate" does not include an administrative fee.110 [(28)] (29)(a) "Reimbursement report" means a report on the adjustment in total111compensation for a claim.112(b) "Reimbursement report" does not include a report on adjustments made pursuant to a113pharmacy audit or reprocessing.114 [(29)] (30) "Retail pharmacy" means the same as that term is defined in Section 58-17b-102.115 [(30)] (31) "Sale" means a prescription drug or prescription device claim covered by a116health benefit plan.117 [(31)] (32) "Spread pricing" means the practice in which a pharmacy benefit manager118charges a health benefit plan a different amount for pharmacist services than the amount119the pharmacy benefit manager reimburses a pharmacy for pharmacist services.120 [(32)] (33) "Wholesale acquisition cost" means the same as that term is defined in 42 U.S.C.121Sec. 1395w-3a.122Section 2. Section 31A-46-103 is enacted to read:12331A-46-103 . Rulemaking.124 In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the125 department may make rules to implement this chapter.126Section 3. Section 31A-46-303 is amended to read:12731A-46-303 . Insurer and pharmacy benefit management services -- Registration128 -- Maximum allowable cost -- Audit restrictions.129 (1) An insurer and an insurer's pharmacy benefit manager is subject to the pharmacy audit-4-Enrolled Copy H.B. 527130 provisions of Section 58-17b-622.131 (2) A pharmacy benefit manager shall not use maximum allowable cost as a basis for132 reimbursement to a pharmacy unless:133 (a) the drug is listed as "A" or "B" rated in the most recent version of the United States134Food and Drug Administration's approved drug products with therapeutic equivalent135evaluations, also known as the "Orange Book," or has an "NR" or "NA" rating or136similar rating by a nationally recognized reference; and137 (b) the drug is:138(i) generally available for purchase in this state from a national or regional139wholesaler; and140(ii) not obsolete.141 (3) The maximum allowable cost may be determined using comparable and current data on142 drug prices obtained from multiple nationally recognized, comprehensive data sources,143 including wholesalers, drug file vendors, and pharmaceutical manufacturers for drugs144 that are available for purchase by pharmacies in the state.145 (4) For every drug for which the pharmacy benefit manager uses maximum allowable cost146 to reimburse a contracted pharmacy, the pharmacy benefit manager shall:147 (a) make a list available to a network pharmacy upon request in a format that:148(i) is electronic;149(ii) is computer accessible and searchable;150(iii) identifies all drugs for which maximum allowable costs have been established;151and152(iv) for each drug specifies:153(A) the national drug code; and154(B) the maximum allowable cost;155 (b) include in the contract with the pharmacy information identifying the national drug156pricing compendia and other data sources used to obtain the drug price data;157 [(b)] (c) review and make necessary adjustments to the maximum allowable cost, using158the most recent data sources identified in Subsection [(4)(a)] (4)(b), at least once per159week;160 [(c)] (d) provide a process for the contracted pharmacy to appeal the maximum allowable161cost in accordance with Subsection (5); and162 [(d)] (e) include in each contract with a contracted pharmacy a process to obtain an163update to the pharmacy product pricing files used to reimburse the pharmacy in a-5-H.B. 527 Enrolled Copy164format that is readily available and accessible.165 (5)(a) The right to appeal in Subsection [(4)(c)] (4)(d) shall be:166(i) limited to 21 days following the initial claim adjudication; and167(ii) investigated and resolved by the pharmacy benefit manager within 14 business168days.169(b) A pharmacy benefit manager shall:170(i) provide as part of the appeals process:171(A) a dedicated telephone number, electronic mail address, and website for the172purpose of submitting appeals; and173(B) the ability for a pharmacy to submit an appeal directly to the pharmacy benefit174manager or through the pharmacy's pharmacy services administrative175organization; and176(ii) allow a pharmacy to submit documentation in support of the pharmacy's appeal177on paper or electronically.178(c) If an appeal is denied, the pharmacy benefit manager shall provide the contracted179pharmacy[ with] :180(i) the reason for the denial[ and] ;181(ii) the identification of the national drug code of the drug that may be purchased by182the pharmacy at a price at or below the price determined by the pharmacy benefit183manager[.] ; and184(iii) the specific basis upon which the pharmacy benefit manager can show that the185drug is available for purchase at or below the maximum allowable cost.186(d) If an appeal is upheld or the pharmacy benefit manager cannot show the drug is187available for purchase at or below the maximum allowable cost for a similarly188situated pharmacy as the pharmacy that submitted the appeal, the pharmacy benefit189manager shall:190(i) make an adjustment for the pharmacy that appealed;191(ii) permit the dispensing pharmacy to reverse the claim and resubmit an adjusted192claim without an additional charge; and193(iii) consider additional action consistent with the outcome of the appeal.194 (6) The contract with each pharmacy shall contain a dispute resolution mechanism in the195event either party breaches the terms or conditions of the contract.196 (7) This section does not apply to a pharmacy benefit manager when the pharmacy benefit197manager is providing pharmacy benefit management services on behalf of the Medicaid-6-Enrolled Copy H.B. 527198 program.199Section 4. Section 31A-46-401 is amended to read:20031A-46-401 . Penalties.201 [A person that violates a provision of this chapter is subject to the penalties202 described in Section 31A-2-308.]203 (1) The commissioner may order a pharmacy benefit manager who violates this chapter to204 forfeit to the state not more than $2,500 for each violation.205 (2) Each day the violation continues is a separate violation.206Section 5. Effective Date.207 This bill takes effect on May 6, 2026.-7-
Pharmacy Pricing Amendments
Sponsors
Rep. Katy Hall (R) sponsors HB 527, and 1 member has co-sponsored it.
Committees
HB 527 went before 3 committees: Rules, Health and Human Services and Economic Development and Workforce Services.
Economic Development and Workforce Services

Economic Development and Workforce Services
Referred to · Feb 27, 2026
History
HB 527 has taken 62 actions since Feb 9, 2026, the latest on Mar 19, 2026.
| Chamber | Action | |||
|---|---|---|---|---|
Mar 19, 2026 | — | Governor Signed in Lieutenant Governor's office for filing | ||
Mar 17, 2026 | House | House/ received enrolled bill from Printing in Clerk of the House | ||
Mar 17, 2026 | — | House/ to Governor in Executive Branch - Governor | ||
Mar 12, 2026 | House | Enrolled Bill Returned to House or Senate in Clerk of the House | ||
Mar 12, 2026 | House | House/ enrolled bill to Printing in Clerk of the House |
Votes
HB 527 went to 6 roll calls across both chambers, the latest on Mar 6, 2026 at 24–0.
| Chamber | Question | Yea | Nay | |||
|---|---|---|---|---|---|---|
Mar 6, 2026 | Senate | Senate/ passed 2nd & 3rd readings/ suspension | 24 | 0 | ||
Mar 6, 2026 | House | House/ concurs with Senate amendment | 66 | 1 | ||
Mar 2, 2026 | Senate | Senate Comm - Favorable Recommendation | 2 | 1 | ||
Feb 27, 2026 | House | House/ passed 3rd reading | 62 | 1 | ||
Feb 24, 2026 | House | House Comm - Substitute Recommendation | 11 | 0 |
Source: le.utah.gov · legiscan.com